IN2014CN00315A - - Google Patents

Info

Publication number
IN2014CN00315A
IN2014CN00315A IN315CHN2014A IN2014CN00315A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A IN 315CHN2014 A IN315CHN2014 A IN 315CHN2014A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A
Authority
IN
India
Prior art keywords
directed
methods
subject matter
disclosed subject
presently disclosed
Prior art date
Application number
Inventor
Peter Lacouture
De Rocha Marcelo Garcia
Daniel B Carr
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014CN00315A publication Critical patent/IN2014CN00315A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The presently disclosed subject matter is directed to methods of treating post operative pain by administering a combination of a lower than minimum approved dose of diclofenac and beta cyclodextrin. The presently disclosed subject matter is also directed to methods of treating pain in high risk or obese mammals in need of analgesia.
IN315CHN2014 2011-07-20 2012-07-19 IN2014CN00315A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509886P 2011-07-20 2011-07-20
PCT/US2012/047453 WO2013013076A1 (en) 2011-07-20 2012-07-19 Methods of treating pain

Publications (1)

Publication Number Publication Date
IN2014CN00315A true IN2014CN00315A (en) 2015-04-03

Family

ID=47558482

Family Applications (1)

Application Number Title Priority Date Filing Date
IN315CHN2014 IN2014CN00315A (en) 2011-07-20 2012-07-19

Country Status (16)

Country Link
US (1) US20140221490A1 (en)
EP (2) EP3257505A1 (en)
JP (2) JP6320917B2 (en)
KR (1) KR20140063583A (en)
CN (1) CN103781484A (en)
AU (1) AU2012283915B2 (en)
BR (1) BR112014001335A2 (en)
CA (1) CA2841964A1 (en)
DK (1) DK2734212T3 (en)
ES (1) ES2646226T3 (en)
IL (1) IL230433A0 (en)
IN (1) IN2014CN00315A (en)
MX (1) MX350463B (en)
MY (1) MY166036A (en)
NO (1) NO2854815T3 (en)
WO (1) WO2013013076A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647348A1 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
EP2818550B1 (en) 2007-05-11 2016-12-28 Adynxx, Inc. Gene expression and pain
EA028911B1 (en) 2007-11-06 2018-01-31 Биоэлектрон Текнолоджи Корпорейшн 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN106661578B (en) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 Oligonucleotide decoys for pain treatment
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20180025116A1 (en) * 2016-07-22 2018-01-25 Arizona Board Of Regents On Behalf Of University Of Arizona Clinical Event Management and Communication System
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
PE20221575A1 (en) * 2020-02-18 2022-10-06 Novo Nordisk As PHARMACEUTICAL FORMULATIONS
CN111494446B (en) * 2020-05-18 2021-08-17 深圳市宝安中医院（集团） Traditional Chinese medicine composition for treating biliary colic and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
PL369966A1 (en) 2002-01-15 2005-05-02 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP1680341B1 (en) * 2003-11-04 2011-05-11 Otis Elevator Company Automatic passenger conveyor slow speed operation
PL1767219T3 (en) 2004-03-10 2010-06-30 Shimoda Biotech Pty Ltd Stable injectable diclofenac compositions
AU2007230718B2 (en) * 2006-03-28 2012-05-10 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
CA2647348A1 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
CN101264086A (en) 2007-03-14 2008-09-17 南京师范大学 Medicinal composition containing cefixime cyclodextrin inclusion compound and preparation thereof
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US7662858B2 (en) * 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain

Also Published As

Publication number Publication date
WO2013013076A1 (en) 2013-01-24
EP2734212A4 (en) 2014-12-24
EP2734212B1 (en) 2017-09-06
CN103781484A (en) 2014-05-07
CA2841964A1 (en) 2013-01-24
MX350463B (en) 2017-09-06
IL230433A0 (en) 2014-03-31
US20140221490A1 (en) 2014-08-07
JP6320917B2 (en) 2018-05-09
AU2012283915B2 (en) 2016-11-24
BR112014001335A2 (en) 2017-02-21
EP2734212A1 (en) 2014-05-28
KR20140063583A (en) 2014-05-27
MX2014000744A (en) 2014-05-14
JP2014520893A (en) 2014-08-25
DK2734212T3 (en) 2017-11-06
JP2017110022A (en) 2017-06-22
AU2012283915A1 (en) 2014-02-06
EP3257505A1 (en) 2017-12-20
ES2646226T3 (en) 2017-12-12
MY166036A (en) 2018-05-21
NO2854815T3 (en) 2018-04-21

Similar Documents

Publication Publication Date Title
IN2014CN00315A (en)
CY1121041T1 (en) METHODS OF TREATMENT OF PEDIATRIC PATIENTS USING DEXMETETOMIDINE
MX2016001901A (en) Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies.
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
BR112014031806A8 (en) gd2 positive cancer treatment method
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX364220B (en) Methods of treating fibrosis.
AR092103A1 (en) LAQUINIMOD IN THE TREATMENT OF DISORDERS MEDIATED BY THE CANABINOID RECEIVER OF TYPE 1 (CB1)
NZ628433A (en) Chitosan-derived compositions
MX2016000220A (en) Regulation of glucose metabolism using anti-cgrp antibodies.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
BR112012006070A2 (en) compositions and methods for treating seizure disorders.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2014006990A (en) Treatment of type i and type ii diabetes.
MX2011007384A (en) Combination therapies for neoplastic disorders.
MX2014001271A (en) Treatment of type 2 diabetes with fty720.
RU2011143250A (en) METHOD OF ANESTHESIA IN SURGICAL TREATMENT OF COSOGLASION IN CHILDREN
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
MX2013006633A (en) Beta-hydroxy-gamma-aminophosphonates for treating immune disorders.